Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DTV58L
|
|||
| Drug Name |
DNL310
|
|||
| Drug Type |
Enzyme replacement
|
|||
| Indication | Mucopolysaccharidosis II [ICD-11: 5C56.31] | Phase 2/3 | [1] | |
| Company |
Denali Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Iduronate 2-sulfatase (IDS) | Target Info | Replacement | [2] |
| BioCyc | Dermatan sulfate degradation (metazoa) | |||
| KEGG Pathway | Glycosaminoglycan degradation | |||
| Metabolic pathways | ||||
| Lysosome | ||||
| Reactome | HS-GAG degradation | |||
| CS/DS degradation | ||||
| WikiPathways | Glycosaminoglycan metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05371613) A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Denali | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.